Patients with end-stage renal disease (ESRD) face higher risks of in-hospital mortality and bleeding with transcatheter aortic valve replacement (TAVR) than patients who aren’t dialysis-dependent, researchers report in the Journal of the American College of Cardiology.

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

Results from the TRILUMINATE study, presented this week at EuroPCR 2019 in Paris, suggest Abbott’s minimally invasive tricuspid valve repair system is an effective solution for patients with structural heart disease, reducing the severity of tricuspid regurgitation (TR) in more than 85% of test cases.

As rates of infective endocarditis among intravenous drug users skyrocket, cardiologists are finding that treating the heart condition without addressing the disease of addiction contributes to readmissions and mortality. 

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR. 

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist. 

Cardiac abnormalities stemming from preterm birth can be corrected with a three-and-a-half-month exercise program in patients’ teens and twenties, according to a drug-free trial of Canadian adults.

The addition of 2.4% hydrogen to hypoxia patients’ traditional ventilation gases improved neurologic outcomes and reduced tissue injury in a recent study of piglets, suggesting hydrogen might be a beneficial addition to therapy for babies undergoing surgery for congenital heart disease (CHD).